Ftse Mib
34.490,71
0,07%
DAX
18.693,37
0,04%
S&P 500
5.304,72
0,70%
NASDAQ
16.920,79
1,10%
Bitcoin
69.092,41
0,82%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ Annexon Inc (ANNX) Annexon Inc (ANNX) Notizie

ANNX

Annexon (ANNX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANNX
DataOraFonteTitoloSimboloCompagnia
13/05/202422:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:ANNXAnnexon Inc
13/05/202422:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:ANNXAnnexon Inc
16/04/202415:00GlobeNewswire Inc.Turnstone Biologics Appoints William Waddill to its Board of DirectorsNASDAQ:ANNXAnnexon Inc
21/02/202422:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:ANNXAnnexon Inc
20/02/202421:15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:ANNXAnnexon Inc
15/02/202402:46Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:ANNXAnnexon Inc
12/02/202422:24Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:ANNXAnnexon Inc
23/01/202423:00Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:ANNXAnnexon Inc
08/01/202402:00GlobeNewswire Inc.Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio for Autoimmune, Ophthalmic and Neurodegenerative DiseasesNASDAQ:ANNXAnnexon Inc
27/12/202312:30GlobeNewswire Inc.Annexon Biosciences to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
22/12/202323:28Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:ANNXAnnexon Inc
21/12/202322:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:ANNXAnnexon Inc
20/12/202323:27GlobeNewswire Inc.Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common StockNASDAQ:ANNXAnnexon Inc
20/12/202323:24Edgar (US Regulatory)Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectusesNASDAQ:ANNXAnnexon Inc
20/12/202323:10GlobeNewswire Inc.Annexon Outlines Global Registrational Program for ANX007 in Geographic Atrophy with FDA Alignment on Vision Preservation as Primary EndpointNASDAQ:ANNXAnnexon Inc
20/12/202323:08GlobeNewswire Inc.Annexon Reports Phase 1 Results for ANX1502, its Oral Small Molecule Inhibitor of the Classical Complement PathwayNASDAQ:ANNXAnnexon Inc
18/12/202322:01GlobeNewswire Inc.Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
22/11/202322:01GlobeNewswire Inc.Annexon Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:ANNXAnnexon Inc
13/11/202312:30GlobeNewswire Inc.Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
09/11/202312:30GlobeNewswire Inc.Annexon Biosciences to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
24/10/202312:30GlobeNewswire Inc.Annexon Receives PRIME Designation from the EMA for ANX007 for the Treatment of Geographic AtrophyNASDAQ:ANNXAnnexon Inc
10/10/202312:30GlobeNewswire Inc.Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal Program in Guillain-Barré Syndrome (GBS)NASDAQ:ANNXAnnexon Inc
19/09/202312:30GlobeNewswire Inc.Annexon Biosciences to Participate in the 2023 Cantor Global Healthcare ConferenceNASDAQ:ANNXAnnexon Inc
18/09/202322:01GlobeNewswire Inc.Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:ANNXAnnexon Inc
07/08/202312:30GlobeNewswire Inc.Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial ResultsNASDAQ:ANNXAnnexon Inc
02/08/202323:06Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:ANNXAnnexon Inc
30/07/202318:00GlobeNewswire Inc.Annexon Presents ARCHER Trial Results at ASRS 2023 Highlighting Potential of ANX007 as a Differentiated Treatment for Geographic AtrophyNASDAQ:ANNXAnnexon Inc
27/07/202312:30GlobeNewswire Inc.Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical OfficerNASDAQ:ANNXAnnexon Inc
24/07/202312:30GlobeNewswire Inc.Annexon to Report ARCHER Phase 2 Trial Results in Geographic Atrophy at ASRS 2023NASDAQ:ANNXAnnexon Inc
22/06/202319:26Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:ANNXAnnexon Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:ANNX

La tua Cronologia

BMF
DIFF25G25
DIFF25G25 - 01/2025
AMEX
MLTI
Credit Suisse X Links Mu...
LSE
ZAMZ
Zamaz
LSE
10I8
BIT
I09898
IT0005575243 20240603 46
EU
P991S
P991S
COIN
STWBTC
NASDAQ
HWEL
Healthwell Acquisition C...
BMF
DIIF33F34
DIIF33F34 - 01/2033
TSX
ONEB
CI ONE North American Co...
AMEX
AVDR
AVDR US LargeCap Leading
BIT
TRVL
Lyxor UCITS ETF STOXX Eu...
BIT
F17973
Vontobel Financial Produ...
BOV
CTGP34
Citigroup DBN MB
COIN
CCBAGBP
BIT
I09912
IT0005575383 20240902 27...
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network